## APPENDIX A

Application No.:09/051,013
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply will the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 9 S 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.888(c).
×	<ol> <li>A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).</li> </ol>
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	<ol><li>The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li></ol>
Γ	7. Other: the topology of the sequence was not reported.
Ar	olicant Must Provide:
×	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entrinto the specification.
×	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
F	or questions regarding compliance to these requirements, please contact:
E	or Rules Interpretation, call (703) 308-4216
F	or CRF Submission Help, call (703) 308-4212
F	or Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

# APPENDIX B

## SEQUENCE LISTING

<110> Bestor, Timothy H.
<120> CHIMERIC DNA-BINDING/DNA METHYLTRANSFERASE NUCLEIC ACID
 AND POLYPEPTIDE AND USES THEREOF

<130> 48075/B/PCT/US
<140> 09/051,013
<141> 1998-10-09
<160> 8

<170> PatentIn Ver. 2.1

<210> 1 <211> 632 <212> DNA

<213> HIV

<400> 1

tggaagggct aattcactc caacgaagac aagatateet tgatetgtgg atetaceaca 60 cacaaggcta etteectgat tageagaact acacacagg gecaggagte agatateeac 120 tgacetttgg atggtgetae aagetagtae cagttgagee agataaggta gaagaggeea 180 acaaaggaga gaacaccage ttgttacace etgtgageet geatgggatg gatgaceegg 240 atatataagt gttagagtgg aggtttgaca geegeetage atteateae gtggeeegga 300 agetgeatee ggagtaette aagaactget gatateegage ttgetacaag ggaettteeg 360 etggggaett teeagggagg egtggeetgg gegggaetgg ggagtggega geeeteage 420 etggageet etetggetag etagggaace etetgggaget etetggeage etagggaace etetgggaeet etetggetag etagggaace eaetgetaa geeteaataa agettgeet 540 gagtgettea agtagtgtg geeegtetgt tgtgtgaete tggtaactag agateeete 600 gaeeeetttta gteagtgtg aaaateteta ge

<210> 2 <211> 513 <212> PRT <213> Spiroplasma

<220>

<223> X in this sequence is unknown

<400> 2

Met Arg Gly Ser His His His His His Gly Ile Cys Thr Thr Met

1 5 10 15

Xaa	Xaa	Xaa 35	Xaa	Xaa	Xaa	Xaa	Xaa 40	Xaa	Xaa	Xaa	Xaa	Xaa 45	Xaa	Xaa	Xaa
Xaa	Xaa 50	Xaa	Xaa	Xaa	Xaa	Xaa 55	Xaa	Xaa	Xaa	Xaa	<b>Xaa</b> 60	Xaa	Xaa	Xaa	Xaa
Xaa 65	Xaa	Xaa	Xaa	Xaa	<b>Xaa</b> 70	Xaa	Xaa	Xaa	Xaa	<b>Xaa</b> 75	Xaa	Xaa	Xaa		Xaa 80
Xaa	Xaa	Xaa	Xaa	Xaa 85	Xaa	Xaa	Xaa	Xaa	Xaa 90	Xaa	Xaa	Xaa	Xaa	<b>Xaa</b> 95	Xaa
Xaa	Xaa	Xaa	Xaa 100	Xaa	Xaa	Xaa	Xaa	Xaa 105	Xaa	Xaa	Xaa	Xaa	Xaa 110	Xaa	Xaa
Xaa	Xaa	Xaa 115	Xaa	Xaa	Xaa	Xaa	Xaa 120	Xaa	Xaa	Xaa	Xaa	Xaa 125	Xaa	Xaa	Xaa
Xaa	Xaa 130	Xaa	Xaa	Xaa	Xaa	Xaa 135	Xaa	Xaa	Xaa	Xaa	Xaa 140	Xaa	Xaa	Xaa	Xaa
Xaa 145		Xaa	Xaa	Xaa	Xaa 150	Xaa	Xaa	Xaa	Xaa	Xaa 155	Xaa	Xaa	Xaa	Xaa	Xaa 160
Xaa	Xaa	Xaa	Xaa	Xaa 165		Xaa	Xaa	Xaa	Xaa 170	Xaa	Xaa	Xaa	Xaa	Xaa 175	Xaa
Xaa	Xaa	Xaa	. Xaa 180		Xaa	Xaa	Xaa	Xaa 185		Xaa	Xaa	Xaa	Xaa 190	Xaa	Xaa
Xaa	Xaa	Xaa 195		Xaa	Xaa	Xaa	Xaa 200		Xaa	Xaa	Xaa	Xaa 205		Xaa	Xaa
Xaa	Xaa 210		. Xaa	Xaa	Xaa	. Xaa 215		Xaa	Xaa	Xaa	Xaa 220	Xaa	Xaa	Xaa	Xaa
Xaa 225		. Xaa	a Xaa	Xaa	230		Хаа	Xaa	Xaa	Xaa 235		Xaa	Xaa	Xaa	Xaa 240
Xaa	a Xaa	a Xaa	а Хаа	. Xaa 245		. Xaa	Хаа	хаа	250		Xaa	Хаа	xaa	255	Xaa
Xaa	a Xaa	a Xaa	260		а Хаа	хаа	Хаа	265	_	xaa	Xaa	Ха	270		. Xaa
Xaa	a Xaa	a Xa	a Xaa	а Хаа	a Xaa	. Xaa	a Xaa	a Xaa	a Xaa	a Xaa	a Xaa	. Xa	а Ха	a Xaa	xaa

275 280 285

Xaa	Xaa 290	Xaa	Xaa	Xaa	Xaa	Xaa 295	Xaa	Xaa	Xaa	Xaa	Хаа 300	Xaa	Xaa	Xaa	Xaa
Xaa 305	Xaa	Xaa	Xaa	Xaa	Xaa 310	Xaa	Xaa	Xaa	Xaa	Xaa 315	Xaa	Xaa	Xaa	Xaa	Xaa 320
Xaa	Xaa	Xaa	Xaa	Xaa 325	Xaa	Xaa	Xaa	Xaa	Xaa 330	Xaa	Xaa	Xaa	Xaa	Xaa 335	Xaa
Xaa	Xaa	Xaa	Xaa 340	Xaa	Xaa	Xaa	Xaa	Xaa 345	Xaa	Xaa	Xaa	Xaa	Xaa 350	Xaa	Xaa
Xaa	Xaa	Xaa 355	Xaa	Xaa	Xaa	Xaa	Xaa 360	Xaa	Xaa	Xaa	Xaa	Xaa 365	Xaa	Xaa	Xaa
Xaa	Xaa 370	Xaa	Xaa	Xaa	Xaa	Xaa 375	Xaa	Xaa	Xaa	Xaa	Xaa 380	Xaa	Xaa	Xaa	Xaa
Xaa 385	Xaa	Xaa	Xaa	Xaa	Xaa 390	Xaa	Xaa	Xaa	Xaa	Xaa 395		Xaa	Xaa	Xaa	Xaa 400
Xaa	Xaa	Xaa	Gly	Gly 405	Arg	Ser	Thr	Ser	His 410		Arg	Xaa	Xaa	Xaa 415	Xaa
Xaa	Xaa	Xaa	Xaa 420	Xaa	Xaa	Xaa	Xaa	Xaa 425		Xaa	Xaa	Xaa	. Xaa 430		Xaa
Xaa	Xaa	Xaa 435		Xaa	Xaa	Xaa	Xaa 440	Xaa	Xaa	Хаа	. Xaa	445		Xaa	Xaa
Xaa	Xaa 450		. Xaa	Xaa	Xaa	Xaa 455	Xaa	Xaa	Xaa	. Xaa	460		Xaa	Xaa	. Xaa
Xaa 465		. Xaa	Xaa	Xaa	. Xaa 470		Xaa	Xaa	Хаа	475		xaa	. Xaa	. Xaa	480
Xaa	Xaa	Xaa	. Xaa	Xaa 485		Xaa	Xaa	Xaa	490		a Xaa	а Хаа	а Хаг	495	
Xaa	. Xaa	Xaa	Xaa 500		Xaa	Xaa	Xaa	Xaa 505		ı Lys	a As	) Lys	510		Gly

Ser

```
<210> 3
<211> 20
<212> PRT
<213> Spiroplasma
<400> 3
Met Arg Gly Ser His His His His His Gly Ile Cys Thr Gly Thr
                  5
Ser His Glu Arg
<210> 4
<211> 23
<212> PRT
<213> Spiroplasma
<400> 4
Gln Lys Asp Lys Lys Ala Gly Ser Ser Val Asp Phe Ala Ile Gly Phe
                                      10
Gly Phe Cys Phe Thr Met Ser
             20
<210> 5
<211> 9
<212> PRT
<213> Spiroplasma
 <400> 5
 Gly Gly Leu Gln Pro Ser Leu Ile Ser
                   5
 <210> 6
 <211> 17
 <212> PRT
 <213> Spiroplasma
 <400> 6
 Met Arg Gly Ser His His His His His Gly Ile Cys Thr Thr Met
                                                           15
                                       10
                   5
```

Ser

4

<210> 7	
<211> 8	
<212> PRT	
<213> Spiroplasma	
<400> 7	
Asp Lys Asp Lys Ala Gly Ser	
1 5	
<210> 8	
<211> 128	
<212> DNA	
<213> Spiroplasma	
<400> 8	
ccatggaatt gtgagcgctc acaattcgcg tcgcgccgac gccgtcgcgg cgacgcgacg	,
cgttggtacc ttaacactcg cgagtgttaa gcgcagcgcg gctgcggcag cgccgctgcg 12	:0
ctgcgcaa 12	. 0

## APPENDIX C

Dkt.48075-B-PCT-US/JPW/JML

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :

Timothy H. Bestor

Serial No.:

09/051,013

Examiner: J. Kerr

Filed

October 9, 1998

Group Art: 1633

For

O AND POMPETIOE AND USES THEREOF

1185 Avenue of the Americas New York, New York 10036

April 4, 2000

Assistation Commissioner for Patents

Washington, D.C. 20231

:

Sir:

## STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same content as that submitted herewith as Exhibit B entitled "Sequence Listing."

Respectfully submitted,

Jane M. Love

Registration No. 42,812

Cooper & Dunham LLP

1185 Avenue of the Americas New York, New York 10036

(212) 278-0400